| National Marrow Donor Program–sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide BE Shaw, AM Jimenez-Jimenez, LJ Burns, BR Logan, F Khimani, ... Journal of clinical oncology 39 (18), 1971, 2021 | 108 | 2021 |
| Graft cryopreservation does not impact overall survival after allogeneic hematopoietic cell transplantation using post-transplantation cyclophosphamide for graft-versus-host … M Hamadani, MJ Zhang, XY Tang, M Fei, C Brunstein, S Chhabra, ... Biology of Blood and Marrow Transplantation 26 (7), 1312-1317, 2020 | 56 | 2020 |
| Hematopoietic cell transplantation with cryopreserved grafts for severe aplastic anemia M Eapen, MJ Zhang, XY Tang, SJ Lee, MW Fei, H Wang, KM Hebert, ... Biology of Blood and Marrow Transplantation 26 (7), e161-e166, 2020 | 42 | 2020 |
| Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplantation cyclophosphamide: Follow-up from a National Marrow Donor … BE Shaw, AM Jimenez-Jimenez, LJ Burns, BR Logan, F Khimani, ... Transplantation and Cellular Therapy 29 (3), 208. e1-208. e6, 2023 | 14 | 2023 |
| Improved overall survival of patients treated with abatacept in combination with a calcineurin inhibitor and methotrexate following 7/8 HLA-matched unrelated allogeneic … LS Kean, LJ Burns, TD Kou, R Kapikian, XY Tang, MJ Zhang, M Hemmer, ... Blood 138, 3912, 2021 | 8 | 2021 |
| Bridging the gap in access to transplant for underserved minority patients using mismatched unrelated donors and post-transplant cyclophosphamide: a national marrow donor … BE Shaw, A Jimenez-Jimenez, LJ Burns, B Logan, F Khimani, BC Shaffer, ... Blood 136, 48-49, 2020 | 7 | 2020 |
| Improved outcomes of UM171–expanded cord blood transplantation compared with other graft sources: real-world evidence S Cohen, N Bambace, I Ahmad, J Roy, X Tang, MJ Zhang, L Burns, ... Blood Advances 7 (19), 5717-5726, 2023 | 6 | 2023 |
| Ixazomib for chronic graft-versus-host disease prophylaxis following allogeneic hematopoietic cell transplantation S Chhabra, A Visotcky, MC Pasquini, F Zhu, X Tang, MJ Zhang, ... Biology of Blood and Marrow Transplantation 26 (10), 1876-1885, 2020 | 5 | 2020 |
| Transplantation using bone marrow from a (very) HLA mismatched unrelated donor in the setting of post-transplant cyclophosphamide is feasible and expands access to underserved … BE Shaw, LJ Burns, B Logan, AM Jimenez-Jimenez, F Khimani, ... Biology of blood and marrow transplantation 26 (3), S283-S284, 2020 | 5 | 2020 |
| A real-world evidence comparison of 1-year overall survival and relapse-free survival between patients treated with abatacept in combination with a calcineurin inhibitor and … LS Kean, LJ Burns, TD Kou, C Bond, R Kapikian, K Lozenski, XY Tang, ... Blood 140 (Supplement 1), 1373-1375, 2022 | 4 | 2022 |
| Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study B Dhakal, MJ Zhang, LJ Burns, X Tang, C Meyer, LW Mau, AK Nooka, ... Haematologica 108 (8), 2249, 2023 | 2 | 2023 |
| Excellent 3-year survival in recipients of mismatched unrelated donor transplants using post-transplant cyclophosphamide: Longer term outcomes of a national marrow donor … B Shaw, AM Jimenez-Jimenez, L Burns, B Logan, F Khimani, B Shaffer, ... BONE MARROW TRANSPLANTATION 57 (SUPPL 1), 385-386, 2022 | | 2022 |
| Corrigendum to'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation'[Biology of Blood and Marrow Transplantation … S Chhabra, A Visotcky, MC Pasquini, F Zhu, X Tang, MJ Zhang, ... Transplantation and cellular therapy 28 (10), 717, 2022 | | 2022 |
| Concordance of efficacy data collected in a clinical trial setting versus a registry study setting: Example of use of real-world data to support drug regulatory approval of … C Bond, TD Kou, L Kean, LJ Burns, K Lozenski, R Kapikian, XY Tang, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 304-304, 2022 | | 2022 |
| Improved Overall Survival of Patients Treated with Abatacept in Combination with a Calcineurin Inhibitor and Methotrexate Following Allogeneic Hematopoietic Stem Cell … LS Kean, LJ Burns, TD Kou, K Lozenski, XY Tang, MJ Zhang, MT Hemmer, ... 2022 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2022 | | 2022 |
